Trials / Completed
CompletedNCT05397223
A Study of Modified mRNA Vaccines in Healthy Adults
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 308 (actual)
- Sponsor
- ModernaTX, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Accepted
Summary
The main goal of this study is to evaluate the safety, reactogenicity, and immunogenicity of study vaccines.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | mRNA-1273 | Sterile liquid for injection |
| BIOLOGICAL | mRNA-1010 | Sterile liquid for injection |
| BIOLOGICAL | mRNA-1345 | Sterile liquid for injection |
| BIOLOGICAL | FLUAD® | adjuvanted (MF59), inactivated, quadrivalent seasonal influenza vaccine |
| BIOLOGICAL | mRNA-1647 | Sterile lyophilized product |
Timeline
- Start date
- 2022-05-24
- Primary completion
- 2026-02-27
- Completion
- 2026-02-27
- First posted
- 2022-05-31
- Last updated
- 2026-03-12
Locations
8 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05397223. Inclusion in this directory is not an endorsement.